Vitamin D in Elderly by Kupisz-Urbańska, Malgorzata et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Vitamin D in Elderly
Malgorzata Kupisz-Urbańska, Jacek Łukaszkiewicz  
and Ewa Marcinowska-Suchowierska
Abstract
Vitamin D deficiency is common in elderly people, especially in patients with 
comorbidity and polypharmcy. In this group, low vitamin D plasma concentration 
is related to osteoporosis, osteomalacia, sarcopenia and myalgia. Vitamin D status 
in geriatric population is an effect of joint interaction of all vitamin D metabolic 
pathways, aging processes and multimorbidity. Therefore, all factors interfering 
with individual metabolic stages may affect 25-hydroxyvitamin D plasma concen-
tration. The known factors affecting vitamin D metabolism interfere with cyto-
chrome CYP3A4 activity. The phenomenon of drugs and vitamin D interactions is 
observed first and foremost in patients with comorbidity. This is a typical example 
of the situation where a lack of “hard evidence” is not synonymous with the pos-
sible lack of adverse effects. Geriatric giants, such as sarcopenia (progressive and 
generalized loss of skeletal muscle mass and strength) or cognitive decline, strongly 
influence elderly patients. Sarcopenia is one of the musculoskeletal consequences of 
hypovitaminosis D. These consequences are related to a higher risk of adverse out-
comes, such as fracture, physical disability, a poor quality of life and death. This can 
lead not only to an increased risk of falls and fractures, but is also one of the main 
causes of frailty syndrome in the aging population. Generally, Vitamin D plasma 
concentration is significantly lower in participants with osteoporosis and muscle 
deterioration. In some observational and uncontrolled treatment studies, vitamin D 
supplementation led to a reduction of proximal myopathy and muscle pain. The 
most positive results were found in subjects with severe vitamin D deficiency and in 
patients avoiding high doses of vitamin D. However, the role of vitamin D in muscle 
pathologies is not clear and research has provided conflicting results. This is most 
likely due to the heterogeneity of the subjects, vitamin D doses and environmental 
factors.
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1. Introduction
Vitamin D is a fat-soluble vitamin mainly produced by the skin after sun 
exposure (cholecalciferol - vitamin D3) and can also be obtained from food (ergo-
calciferol-vitamin D2 and vitamin D3) or supplementation. In the liver, vitamin D 
(the term “vitamin D” refers both vit.D2 and vit.D3”) is converted to 25-hydroxyvi-
tamin D [25(OH)D]), also known as “calcidiol”, the major circulating metabolite 
of vitamin D which can be measured in the blood. In the kidney, [25(OH)D] is 
converted by 1-alfa-hydroxylase into its active form called 1,25-dihydroxyvitamin D 
[1,25(OH)2D], also known as “calcitriol”, that plays a vital role in maintaining bone 
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homeostasis by regulating calcium metabolism. This action of [1,25(OH)2D] is 
referred to as endocrine action. The other area where [25(OH)D] is converted by 
peripheral 1-alfa-hydroxylase to [1,25(OH)2D] are cells in various tissues. There, 
[1,25(OH)2D] regulation by autocrine or paracrine actions have been observed.
Vitamin D deficiency and insufficiency is one of the major world-wide health 
problems and its consequences seem to be more serious in the elderly population 
than in younger adults. It has been associated with a wide range of diseases includ-
ing autoimmune diseases (among others multiple sclerosis, type 1 diabetes, rheu-
matoid arthritis), cardiovascular diseases (for example stroke), infectious diseases 
(bacterial, viral and, fungal), type 2 diabetes and some types of cancers (colorectal, 
breast and prostate gland). It is also recognized that vitamin D deficiency is associ-
ated with some psychiatric disorders including depression, neurocognitive dysfunc-
tion and others forms of neurodegenerative disorders (Alzheimer’s disease) [1].
This recognition has not only resulted in broadening our knowledge and more 
conscious vitamin D prescriptions but also led to the crucial question in everyday 
clinical practice: How can we use our knowledge to improve care for elderly people 
with vitamin D deficiency and to guide future research studies? Therefore, our 
publication is focused on distinctive characteristics of vitamin D metabolism, 
deficiency and drug interaction in the elderly population. As the range of aspects of 
vitamin D effects in the geriatric population is extremely wide, only chosen ele-
ments typical for elderly patients could be presented to emphasise the complexity of 
the issue.
2. Vitamin D deficiency in the aging population
Available data indicates that in many countries all over the world, the general 
population (irrespective of the latitude of residence, age, sex and race) and patients 
considered as otherwise healthy, suffer from vitamin D insufficiency, defined as 
25(OH)D < 30 ng/ml. Recent large observational data have suggested that ~40% 
of Europeans are vitamin D deficient, and 13% are severely deficient [2]. When 
25-hydroxyvitamin D levels were analyzed in relation to age (based on 10-year 
ranges) there were significant differences in the level of 25(OH)D. The level of 
25(OH) D was significantly lower in the older population. However, there are 
conflicting data concerning the subject, for example in a large Japanese study, the 
adjusted odds ratio for circulating 25OHD > 75 nmol/l (>30 ng/ml) was in men and 
women aged >70 years (reference group: individuals aged <50 years) 2.55 and 2.26, 
respectively. In Bergman et all study, patients aged over 65 years had significant 
lower circulating 25OHD levels than patients over 75 years [3–6].
3. Elderly people are not a homogenic population
Meanwhile, the elderly and the oldest-old are one of the fastest growing popula-
tions all over the world. The number of people aged 65 and older is expected to 
rapidly increase in the next decades. Not only the elderly, but also the oldest old 
are still increasing in numbers. Globally, the current average annual growth rate 
of people aged 80 years or older (3.8 per cent) is twice as high as the growth rate 
of the persons younger than 60 years of age (1.9 per cent) [7]. Despite the same 
range of biological age, it is not a homogenic population regarding the aging type 
(successful or unsuccessful). Multimorbidity combined with polypharmacy is 
common, so functional assessment and mobility determine the quality of life. The 
role of vitamin D in the prevention and treatment of diseases associated with aging 
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is still being researched. Therefore, during last decade, geriatric medicine has been 
focused on studies concerning not only vitamin D deficiency in elderly, but espe-
cially on its possible impact on Healthy life years (HLY, also called disability-free 
life expectancy) taking into account the role of vitamin D considered as a potential 
factor strongly influencing possible elongation of HLY. Vitamin D status has been 
widely studied in the last decade. Undoubtedly, one of the most important clinical 
question concerns the possibilities of preventing of unhealthy aging.
4. Factors contributing to vitamin D deficiency in the elderly
Most importantly, [1,25(OH)2D] directly or indirectly regulates over 200 
genes including those involved in: rennin production in the kidney, insulin in the 
pancreas, the release of cytokines from lymphocytes, production of cathelicidin by 
macrophages, and the growth and proliferation smooth muscle cells and cardiomy-
ocytes. The main cause of aging-associated vitamin D deficiency is low vitamin D 
production. As we age, there is a reduction in the skin’s concentration of 7-dehy-
drocholesterol [8]. Specifically, for each decade past the age of 40, there is approxi-
mately a 10 to 15% decrease in the level of 7-dehydrocholesterol. Furthermore, 
the character of dressing style makes the sun exposure indispensable as well as 
short time of outdoor activities, taking into account that a sufficient amount of 
sunlight radiation for vitamin D production by the skin only occurs between May 
and September in some latitudes. Additionally, there is about a 35% decrease in 
intestinal calcium absorption after the age of 70 [9]. This decrease is even greater 
in women because of reduced fractional calcium absorption and estrogen changes 
after the menopause with increased urinary calcium losses [10]. Other causes of 
aging-associated vitamin D deficiency are related to poor vitamin D and calcium 
nutrition. With age, comorbidity must also be taken into account with a special 
focus on renal and liver insufficiency.
5. Vitamin D and geriatric giants
With advanced age, people appear to change their health status perception as a 
range of independence rather than lack of disease. The presence of “geriatric giants” 
(coined by Bernard Isaacs in 1965 to encompass common impairments) contributes 
to more serious consequences than in younger groups [11–13]. Recent epidemiologi-
cal research has shown that the concentration of 25-hydroxyvitamin D may have 
an impact on various age-related diseases, as well as on geriatric giants. Geriatric 
giants are common, have multiple contributing factors and their consequences are 
stronger in older groups of patients. Some geriatric giants, like sarcopenia, falls 
or cognitive decline, neurodegenerative disease, and depression are likely to have 
extremely strong impact on independency of individuals and high risk of negative 
outcomes.
5.1 Sarcopenia
Sarcopenia is known as a new geriatric giant. It is an interdisciplinary and mul-
tifactor symptom whose prevalence rises with age. Furthermore, the development 
of secondary hyperparathyroidism favors a negative calcium balance, high bone 
turnover and accelerates age-related bone loss and osteoporotic fractures.
According to the consensus of The European Working Group on Sarcopenia in 
Older People, the diagnosis is based on three criteria: low muscle strength or/and 
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low physical performance, and low muscle mass. Sarcopenia is a progressive process 
and, as a new geriatric giant, has many contributing factors - not only the aging 
processes, but also vitamin D deficiency, diet, sedentary lifestyle, diseases, drug 
treatments and drug interactions [14].
Sarcopenia has strong impact on the outcomes of the risk of falls and osteopo-
rotic fractures, lack of independency and lack of ability to perform activities of 
daily living. Subjects with sarcopenic obesity in the MrOS study had a 1.9 increased 
risk of any fracture and 3.1 increased risk of spine fracture [15]. The loss of strength 
is also an important criteria for a diagnosis of frailty syndrome (FS). Therefore, 
sarcopenia associated with muscle loss in frailty syndrome is one of the major issues 
of geriatric medicine. The prevalence of frailty syndrome is growing with age. The 
key role that vitamin D plays in muscle function and low muscle strength has been 
described in subjects with osteomalacia. The effects of 1,25(OH)D on the prolifera-
tion and differentiation in myogenic cells have also been described [20]. Although it 
remains highly debated, the action of vitamin D via the VDR receptor seems to play 
a significant role in muscle development and growth [16–18].
It remains unclear in observational studies if there is a key role in vitamin D 
interaction with muscle, or rather this is the effect of other factors. In an eight-
year longitudinal study, the supplementation of vitamin D was not associated 
with a decreased risk of frailty, but the average daily dosage of oral vitamin D was 
lower than 400 IU and probably not enough to achieve the target of serum 25(0H)
D concentration of 20 ng/ml. Additionally, the lowest 25(OH)D season-specific 
quartile correlated with a faster rate of muscle strength loss in men aged over 85 
[19, 20]. The process was observed in all subjects, including those who were not 
supplemented with vitamin D. Some interventional studies have been conducted 
to describe the role of vitamin D in musculosceletal health. However, only a few of 
these studies had muscle strength as the endpoint. Vitamin D may affect muscle 
function, particularly in vulnerable populations such as the oldest old and patients 
with severe sarcopenia. However, it is difficult to create a homogenic group of sub-
jects with the oldest old due to a large number of cofactors that influence physical 
performance. Nevertheless, vitamin D supplementation for preventing sarcopenia 
still requires a controlled, double–blind research design.
Sarcopenia being one of the crucial factors of frailty syndrome constitution 
provides a significant increase in falls that are one of the many causes of disability 
and functional decline in elderly people. Despite numerous trials and meta-analyses 
conducted the efficacy of vitamin D supplementation as a mean to prevent falls 
remains uncertain. The effectiveness of vitamin D in fall prevention remains an 
issue of the debate. Authors of publications have underscored the importance of 
further trials on vitamin D and falls and highlight 3 key characteristics these trials 
should comprise: vitamin D deficiency, vitamin D administration, and unified falls 
documentation [21].
5.2 Cognitive decline: dementia, depression
Vitamin D, by direct and indirect regulation of more than 200 genes, exerts 
bioactivity as a hormone and plays an important role in processes important for 
the functioning of all systems as well as central nervous system, including calcium 
absorption, tissue and immune cell growth, and inflammation. However, the cru-
cial role of vitamin D for brain health is supported by the presence of the enzyme 
that produces its active form 1-hydroxylase in cerebrospinal fluid. The receptor for 
the active metabolite is found throughout the human brain. Vitamin D has been 
linked with neuron growth and survival by its regulation of factors such as gluta-
thione, growth factors, neurotrophies and neurotransmitters. Moreover, in animal 
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models, vitamin D supplementation showed reduced inflammatory biomarkers in 
the hippocampus. Vitamin D receptor (VDR) seems to be one of the most probable 
genetic factors of Alzheimer disease (AD). VDR polymorphism increases the risk of 
AD by 2.3 times and in molecular studies, vitamin D treatment prevented amyloid 
production and enhanced its removal [22].
The pleiotropic aspects of vitamin D action was tested in numerous observa-
tional studies suggesting an association between low serum concentration and 
the increased risk of other geriatric giants such as cognitive decline, dementia and 
depression and its supplementation has also shown an improvement in the cognitive 
performance in elderly patients with senile dementia.
5.2.1 Epidemiological studies
A survey was conducted in Norway among patients over 65 years old with 
depression who were admitted to psychiatric wards. Vitamin D deficiency (below 
20 ng/ml) was observed in 71% patients with depression, 50% patients with bipolar 
affective disorder and in 25% of control group patients. However, in other studies, 
there exist a wide range of differences between vitamin D deficiency status (from 
34,6% in USA to 100% in British research). Because of the existing conflicts in the 
data, Li et all in 2018 conducted a meta-analysis to extend the knowledge concern-
ing vitamin D deficiency in patients with depression. They assumed that for every 
10 ng/ml of vitamin D level, the increase risk of depression decreases 12%. So, 
vitamin D supplementation could be useful in the reduction of depression risk, but 
until this time, the data of RCT’s are not conclusive [23, 24].
5.2.2 Alzheimer’s disease (AD)
Two meta-analysis underscored significantly lower vitamin D concentrations in 
patients with AD compared to healthy individuals. The risk of AD in patients with 
vitamin D deficiency was found to be twice higher in an American study and 2.85 
times higher in a French study. There exists a correlation between the stage of defi-
ciency and concentration - respectively 19% for concentration below 20 ng/ml and 
31% for severe deficiency (<10 ng/ml). However, concentrations >35 ng/ml were 
not correlated with a of lower risk of AD. Vitamin D pretends to be an independent 
protective factor reducing Alzheimer diseases processes. For example, in a Spanish 
study, the dynamics of Alzheimer disease was slower in patients receiving vitamin D.  
However, the data concerning influence of vitamin D supplementation in AD 
remains not conclusive [25, 26]. There is also lack of prospective RCT studies.
6. Comorbidity and infections
Notably, several studies have reported an inverse association between 25(OH)D 
serum levels and the risk of infections (including oral, gastrointestinal, urinary, and 
respiratory). Many studies underscored the potential immunomodulatory effects 
as well as the association between the low serum vitamin D levels and many other 
diseases, such as endocrinal dysfunction leading to increasing insulin resistance, 
diabetic negative outcomes (for example retinopathy), and cardiovascular disor-
ders. Therefore, all those elements of diseases, typical for elderly patients, create 
unfavourable background for constitution and progression of geriatric giants. 
However, in a Lithuanian cross-sectional study (Alekna et al.) of serum 25(OH)D 
concentrations in relation to activities of daily living (ADL) conducted among octo-
genarians the regression coefficient for 25(OH)D concentration vs. ADL category 
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was 0.2 (p = 0.01). As highlighted by the authors, it was impossible in this study to 
determine whether ADL status was a cause or an effect of serum 25(OH)D concen-
tration [27] Complexity of aging processes, age related diseases, geriatric giants and 
socioeconomic factors influencing elderly patients result in multifactorial, elaborate 
relation between all this factors to vitamin D status.
The last several months have strongly influenced geriatric medicine. COVID 
infection has become a clinical example of how important the role of vitamin D is 
in immunomodulation and anti-inflammatory effect for organisms in particular of 
aging organs.
7. Vitamin D supplementation and vitamin D treatment in elderly
7.1 Recommendations for general elderly populations
Recommendations for vitamin D intake in asymptomatic healthy individu-
als and in asymptomatic healthy individuals at high risk of vitamin D deficiency 
(which was published as the Central European Recommendation; similar to the 
Endocrine Society in USA) are presented in Tables 1 and 2. These guidelines recom-
mend the use of vitamin D supplements to obtain and maintain the optimal target 
25(OH)D concentration in range of 30-50 ng/ml (75-125 nmol/m).
As presented in Tables 1 and 2, people over the age of 65 should take  
800- 2000 IU/d of vitamin D throughout the whole year, but people younger than 
65 should take vitamin D in the same doses only when the photosynthesis in the 
skin is insufficient, during the winter months at latitude of >40°, little or no UVB 
radiation reaches the surface of the earth; such as in Poland from October to March 
(Table 1). The recommended vitamin D intake for groups at risk of vitamin D defi-
ciency and requires larger doses of vitamin D (Table 2). This includes night-time 
workers and dark-skinned people (1000-2000 IU/d of vitamin D for the whole 
year) and obese people (1600 IU/d to 4000 IU/d for the whole year). There are two 
essential points about supplementation in the healthy population. First, measure-
ments of [25(OH)D] should not be tested before and during supplementation 
and second, vitamin D doses larger than the tolerable upper intake levels (ULS) 
to prevent deficiency of vitamin should not be prescribed. The ULS for adults and 
seniors with normal body weight is 4000 IU/d, but in obese adults and seniors, it is 
higher (10 000 IU/d.) [28].
It is very important that treatment of vitamin D deficiency is based on 25(OH) D 
concentration and antecedent prophylactic management. Individual patients with 
serum 25(OH) < 20 ng/ml that have clinical risk factors for vitamin D deficiency 
(decreased intake, gastrointestinal diseases, chronic hepatic diseases, renal diseases, 
medication with antiepileptic drugs and others which disturbing metabolism of 
vitamin D) with bone diseases (fragility fractures, documented osteoporosis or 
Sufficient skin synthesis Supplementaion vitamin D IU
Season in year October–March April–September October–March April-September




Recommendation: do not routinely test 25 (OH)D levels in these groups
Table 1. 
Recommended vitamin D intake in asymptomatic healthy individuals at high risk of vitamin D deficiency.
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high fracture risk, treated with antiresorptive medication, osteomalacia) should be 
treated. The primary treatment objectives for vitamin D deficiency are the prescrip-
tion of adequate doses to ensure correction of vitamin D deficiency (>20 ng/ml), 
reversing the clinical consequences of vitamin D in a timely manner and avoiding 
toxicity.
The oral route (intake) of treatment is recommended (vitamin D2 and vitamin D3) 
and should be taken with food to aid absorption. The dosage should be adjusted on 
the basis of the baseline deficit and the patient’s weight (schematic representation for 
elderly population presented below in the Figure 1). The control level of [25(OH)D] 
should be attained during treatment at the beginning and after 7-10 weeks.
Treatment of vitamin D deficiency should consist of 2 parts: the initial reple-
tion phase of therapy (loading phase), and after the loading phase, initiating the 
maintenance.
The loading phase with vitamin D requires 7 to 10 weeks. The aim is to saturate 
all body compartments so the level of [25(OH)D] is above 30 ng/ml (75 nnom/l. 
During this time, loading doses of vitamin D (about 300 000 IU) should be given as 
daily split (divide) doses or intermittent doses every week. Single mega doses (300 
000 IU to treat deficiency) are not recommended in the treatment of vitamin D 
deficiency. Maintenance regiments may be considered after the loading doses.
Example regiments: all loading doses are 300 000 IU and may by administered 
by a weekly or daily split.
Sufficient skin synthesis Supplementaion vitamin D IU









Recommendation: do not routinely test 25 (OH)D levels in these groups
Table 2. 
Recommended treatment for individual patients with vitamin D deficiency.
Figure 1. 
Schematic representation elderly population vulnerable to vitamin D deficiency that defines broad groups 
for clinical consideration and decision-making about supplementation or treatment with vitamin D elderly 
individuals’ (PVDD – patients with vitamin D deficiency).
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50 000 IU capsules, one given weekly for 6 weeks.
20 000 IU capsules, two given weekly for 7 weeks.
1000 IU capsules, 4 a day for 10 weeks.
Maintenance regiments after loading doses (given either daily (800 – 4000 IU/D) 
or intermittently at higher equivalent doses (20 000 every 2 weeks).
The rapid correction of vitamin D deficiency may be necessary in some patients. 
Rapid correction is required in patients with symptomatic disease or those about 
to start treatment with potent antiresorptive agent, such as zolenndronate or 
denosumab. In these cases, the recommended treatment is based on split-loading 
doses (not single large doses) followed by regular maintenance therapy. Regarding 
the differences between cholecalciferol and calcifediol, including faster intestine 
absorption of the calcifediol and linear increment uninfluenced by baseline 
 vitamin D level, in elderly patients often this type of therapy should be considered.
Less urgent correction with lower subsequent dosing is required in patients 
with increased sensitivity to vitamin D therapy because of genetic abnormality in 
vitamin D metabolism, co-morbidities such as CD, granulomatoforming diseases or 
hyperparathyreoidismus [29, 30] .
Analogs 1 alfa (OH)D, 1, alfa 25(0H2)D and others should not be used in 
therapy of vitamin D deficiency or insufficiency. It is worth of mentioning that in 
the elderly patients, presence of geriatric giants, multimorbidity and drug interac-
tions should be taken into account.
8. Vitamin D intake and polypharmacy
The problem of polypharmacy and drug interaction is common in geriatric 
patients, as multimorbidity is a typical characteristic of this population. This makes 
it necessary to take into account assumptions concerning the possible interferences 
of widely used drugs on vitamin D metabolism. Vitamin D status in humans is an 
effect of the joint interaction of all vitamin D metabolic pathways. Therefore, all 
factors that interfere with individual metabolic stages may affect 25-hydroxyvita-
min D concentration in the circulation. To date, there is little hard evidence that 
agents such as lipase inhibitors, statins, antimicrobials, antiepileptics and others 
affect [25(OH)D] concentration in blood serum. The issue of drug and vitamin D 
interactions is a clear example of a situation where lack of evidence does not equate 
to “no harm”.
The agents with a potential to influence vitamin D status can be roughly divided 
into drugs that effect vitamin D intestinal absorption and those that influence 
vitamin D metabolism [31].
Included in the first category, lipase inhibitors are widely used for obesity treat-
ment. They decrease triglycerides hydrolysis in the gut, causing an incremental rise 
of excreted fat from the typical 5% up to 30%. This increases fat-soluble vitamin D  
loss in the feces, at the same time decreasing the vitamin D pool available for 
absorption in the small intestine. In the second category of drugs that influence 
vitamin D metabolism, statins are an important class and are widely used as very 
effective agents in both the primary and secondary prevention of cardiovascular 
diseases.
Statins are the most widely prescribed cholesterol-lowering drugs in the world, 
and they are expected to generate a revenue over $1 billion by 2025. All statins 
function as inhibitors of a rate-limiting enzyme in synthesis of cholesterol, 
namely hydroxyl-methyl coenzyme A (HMG-CoA) reductase. This action brings 
statins close to vitamin D metabolism, at the same time suggesting their uniform 
action and similar side effects. Nevertheless, the results of numerous studies show 
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that the statins/vitamin D interaction give diverse and pleiotropic results. This 
is evident by a meta-analysis that was “inconclusive on the effects of statins on 
vitamin D with conflicting directions from interventional and observational stud-
ies”. Although the fundamental mechanism of action is identical for all the statins, 
they differ in water solubility, and are catabolized in different ways depending 
on the statin type, patient’s age and vitamin D status, nutritional conditions 
and insolation. There are two basic ways of the disposition of statins from the 
human body. One is degradation of some statins in the stomach and excretion as 
native compounds, the second is an oxidative pathway where the statins undergo 
modification by a specific cytochrome P450 isoenzymes resulting in an enhanced 
solubility and subsequent excretion. Some of those enzymes belong to the CYP3A 
family, and that is the meeting point of the vitamin D and statins catabolic 
pathways [32].
It is known that atorvastatin, lovastatin and simvastatin are primarily 
metabolized by CYP3A4, a multi-substrate cytochrome involved also in vitamin D 
metabolites catabolism. Cytochromes in the CYP3A category are also very impor-
tant enzymes in the vitamin D catabolic pathways. Therefore, any interference 
with their activity may cause a disturbance in the vitamin D status of the patient. 
It is known that some statins may compete for the active centers of the CYP3A 
enzymes, slowing down the catabolism of the vitamin D metabolites. This results in 
the vitamin D status increasing, especially in patients who are supplemented with 
vitamin D. It has been found that atorvastatin treatment significantly increases 
25-hydroxyvitamin D concentration in patient’s blood serum. This increase is 
especially visible in patients treated with 800 IU of vitamin D per day. This effect is 
probably due to inhibitive competition of vitamin D metabolites and the statin for a 
limited number of active centers available in CYP3A4, and therefore the decrement 
of the metabolic clearance of the vitamin D metabolites. There are also reports that 
statins (e.g., rosuvastatin) that are not metabolized by CYP3A4 correlate with the 
increased 25OHD concentrations in the circulation system of the patient. There 
is no simple explanation for this finding. One possibility is that statins may act as 
inducers of the vitamin D 25-hydroxylase activity expressed to a certain extend by 
the CYP3A4 [33].
Statins are also known to increase the catabolic clearance of vitamin D metabo-
lites. The mechanism of this phenomenon relays on their affinity for nuclear recep-
tors (PXR, CAR) involved in regulating the expression of CYP3A proteins. [34].
Antiepileptics (AEDs) as carbamazepine, oxcarbazepine, phenobarbital, phe-
nytoin, primidone, and valproate have all been associated with bone health prob-
lems in epileptic patients. Taking into account that some of them are prescribed as 
coanalgesics, this type of therapy is widely use in clinical practice among elderly 
patients. AEDs are known to induce the enzymes from the catabolic pathway of 
the vitamin D. This action results in a specific sequence of events leading to an 
increased fracture risk beginning with the induction of hepatic cytochromes and 
accelerated degradation of the vitamin D metabolites. AEDs can result in decreased 
vitamin D status and decreased intestinal calcium absorption that has a nega-
tive effect on the circulating calcium pool. In turn, this activates a compensatory 
increase in PTH concentrations resulting in increased bone resorption and an 
increased risk of fractures. The negative effects of anticonvulsants on fracture 
risk were confirmed by a population-based analysis. The study had nearly 16,000 
participants who had a nontraumatic fracture of the wrist, hip and vertebra with 
up to 3 matched controls (“n” around 47,000). A significant increase of fracture 
risk was found for most of the antiepileptic drugs investigated namely for carbam-
azepine, clonazepam, gabapentin, phenobarbital and phenytoin. OR values ranged 
from 1,24 for clonazepam to 1,91 for phenytoin. Valproic acid was the only AED 
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not associated with increased fracture risk. These results are consistent with other 
population-based studies [35, 36].
Research was conducted to determine if vitamin D supplementation improves 
the bone condition in patients taking anti-epileptic drugs. The results of a system-
atic review of 9 studies reported that the research was marred by very little unifor-
mity with respect to the vitamin D dosing regimen, sample sizes, the antiepileptic 
drugs used, study length and design and bone outcomes measured. Nevertheless, 
the review states that vitamin D supplementation seems to have a positive effect on 
bone turnover markers, especially alkaline phosphatase and bone mineralization in 
adults with epilepsy.
The mechanisms of action and observational data suggest that other factors 
might interfere with the metabolism of vitamin D. This group comprises of gluco-
corticoids, immunosuppressive agents (cyclosporine, tacrolimus), many chemo-
therapeutic agents, highly active antiretroviral agents, and histamine H2-receptor 
antagonists.
Glucocorticoids belong to a widely used class of drugs. Prednisone, hydrocorti-
sone, dexamethasone are used in adrenal replacement, immune suppression and 
chemotherapy. The well-known side-effect of their application is osteoporosis. 
Therefore, alterations in vitamin D metabolism have been investigated as a possible 
mechanism. It has been found that glucocorticoids induce several P450 cyto-
chromes in a way similar to AED, including the vitamin D catabolizing CYP2A4. 
Although the RCT class studied failed to produce conclusive results, a recent 
overview of systematic literature revealed that the prevalence range of fractures or 
osteoporosis in patients taking glucocorticoids is 21 to 30%. The postulated remedy 
for these problems, save for decreasing the glucocorticoids dose, is vitamin D 
supplementation [37, 38].
9. Other drugs
One of published metanalysis underscored undoubted need for further research 
to understand the impact of drugs that inhibit CYP enzyme activity related to 
vitamin D status. Regarding such treatment as the antimicrobial agent ketoconazole 
or proton pump inhibitor omeprazole, have been shown to inhibit both CYP3A4 
166, 167 and CYP24 168 in vitro, so far, no studies have evaluated the clinical effect 
of these drugs on human vitamin D status in elderly [39].
10. Vitamin D toxicity in elderly
Vitamin D toxicity (VDT) due to excess of vitamin D is a clinical condition 
characterized by severe hypercalcemia that may persist for a prolonged period of 
time and lead to serious health consequences. Hypervitaminosis D with hyper-
calcemia develops after uncontrolled use of vitamin D mega doses or vitamin D 
metabolites [25(OH)D, 1,25(OH)2D]. Hypervitaminosis D may develop in some 
clinical conditions as a result of using vitamin D analogs (exogenous VDT). 
Hypervitaminosis D with hypercalcemia may also be a manifestation of excessive 
production of 1,25(OH)2D in granulomatous disorders such as sarcoidosis, tuber-
culosis, leprosy, fungal diseases, giant cell polymyositis, and berylliosis. In healthy 
geriatric population, exogenous vitamin D toxicity may be caused by prolonged 
use (months) of vitamin D mega doses, but not by the abnormally high exposure 
of skin to the sun or by eating a diversified diet. Exogenous VDT due to vitamin D 
overdosing is diagnosed in the elderly similar as in younger people (very rare) by 
11
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markedly elevated 25(OH)D concentrations (>150 ng/ml) accompanied by severe 
hypercalcemia and hypercalciuria and by very low or undetectable parathyroid 
hormone (PTH) activity [40, 41].
Exogenous VDT can be the result of patients taking excessive amounts of 
1,25(OH)2D or other 1–hydroxylated vitamin D analogs [1(OH)D], for example 
paricalcitol and doxercalciferol, used to treat hypercalcemic disorders, including 
hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, and end- stage 
renal failure. When this occurs, hypercalcemia is a harmful side effect of treatment 
with a pharmacological vitamin D agent that is not related to 25(OH)D concentra-
tion and when the concentration value of 1,25(OH)2D is elevated. The increased 
risk of endogenous VDT is a serious clinical issue in the elderly with granuloma-
forming disorders and in lymphomas. Patients with granuloma-forming disorders 
and lymphomas are hypersensitive to vitamin D. Elevated 1,25(OH)2D concentra-
tion with hypercalcemia may develop after vitamin D supplementation, from 
dietary products fortified with vitamin D or after sunbathing. In granulomatous 
diseases (including tuberculosis, sarcoidosis, leprosy, fungal diseases, infantile 
subcutaneous fat necrosis, giant cell polymyositis, and berylliosis) endogenous 
VDT is related to the abnormal extrarenal synthesis of 1,25(OH)2D by activated 
macrophages. In lymphomas, the etiology of VDT is multiple, heterogeneous, and 
still not fully recognized. In endogenous VDT, hypercalcemia is related to increased 
1,25(OH)2D concentration. In contrast, hypercalcemia is a consequence of high 
25(OH)D concentration due to an overdose of vitamin D (exogenous VDT) [42, 43].
Over the last decade, the Institute of Medicine (IOM) and the Endocrine 
Society have both concluded that acute VDT is extremely rare in the literature, 
that serum 25(OH)D concentrations must exceed 150 ng/ml (375 nmol/l). Other 
considerations, such as calcium intake, can have an effect the risk of hypercalce-
mia and VDT. Despite of the risk factors associated with VDT, there is empirical 
evidence that vitamin D is among the least toxic fat-soluble vitamins, and sig-
nificantly less toxic than vitamin A. Dudenkov and colleagues researched more 
than 20,000 serum 25(OH)D measurements performed at the Mayo Clinic from 
2002 to 2011 to determine the prevalence of VDT, demonstrated by the presence 
of hypercalcemia. The number of individuals with a serum 25(OH)D concentra-
tion > 50 ng/ml (>75 nmol/l) had increased by 20 times during that period. On 
the other hand, high 25(OH)D concentrations can coincide with normal con-
centrations of serum calcium. In this study, only one patient was diagnosed with 
hypercalcemia with a 25(OH)D concentration of 364 ng/ml (910 nmol/l). Pietras 
and colleagues [16] reported no evidence of VDT in healthy adults in a clinical 
setting who received 50,000 IU of vitamin D2 once every 2 weeks (equivalent to 
approximately 3,300 IU/day) for up to 6 years. These patients maintained 25(OH)
D concentrations of 40–60 ng/ml (100–150 nmol/l). Ekwaru and colleagues had 
similar findings of no evidence of toxicity in Canadian adults who received up 
to 20,000 IU of vitamin D3 per day and had a significant increase of 25(OH)D 
concentrations, up to 60 ng/ml (150 nmol/l) [44–47].
11. Conclusions
The world-wide prevalence of vitamin D deficiency and its role in the main-
tenance of skeletal and non-skeletal health calls for continuing investigation of 
vitamin D. These actions should take into account a multitude of confounding 
variables, including age – elderly as well as the oldest-old, presence of geriatric 
giants and their consequences, evaluation of vitamin D deficiency as symptomatic 
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the way of supplementation/treatment, polypharmacy and potential drug interac-
tions. All these factors lead us to define the broad groups for clinical consideration 
and decision-making regarding the supplementation or treatment with vitamin D 
in elderly individuals. Heterogeneity of the elderly population contributes to mak-
ing impossible the creation one, simple algorithm for every patient.
Therefore, the proposed strategy (presented above in the Figure 2) to prevent 
vitamin D deficiency and the negative outcomes in the general elderly population 
in everyday clinical practice, takes into account multifactorial character of geriatric 
patient.
Figure 2. 
Proposed strategy for geriatric patient with vitamin D deficiency.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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provided the original work is properly cited. 
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